Format

Send to

Choose Destination
See comment in PubMed Commons below
Sci Rep. 2014 Jan 17;4:3743. doi: 10.1038/srep03743.

Chemical signatures and new drug targets for gametocytocidal drug development.

Author information

1
1] National Center for Advancing Translational Sciences, National Institutes of Health, Bethesda, MD 20892, United States [2].
2
1] Laboratory of Malaria and Vector Research, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20892, United States [2].
3
Department of Biology, Loyola University Chicago, Chicago, IL 60660, United States.
4
National Center for Advancing Translational Sciences, National Institutes of Health, Bethesda, MD 20892, United States.
5
1] Laboratory of Malaria and Vector Research, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20892, United States [2] Department of Biology, Loyola University Chicago, Chicago, IL 60660, United States.

Abstract

Control of parasite transmission is critical for the eradication of malaria. However, most antimalarial drugs are not active against P. falciparum gametocytes, responsible for the spread of malaria. Consequently, patients can remain infectious for weeks after the clearance of asexual parasites and clinical symptoms. Here we report the identification of 27 potent gametocytocidal compounds (IC50 < 1 μM) from screening 5,215 known drugs and compounds. All these compounds were active against three strains of gametocytes with different drug sensitivities and geographical origins, 3D7, HB3 and Dd2. Cheminformatic analysis revealed chemical signatures for P. falciparum sexual and asexual stages indicative of druggability and suggesting potential targets. Torin 2, a top lead compound (IC50 = 8 nM against gametocytes in vitro), completely blocked oocyst formation in a mouse model of transmission. These results provide critical new leads and potential targets to expand the repertoire of malaria transmission-blocking reagents.

PMID:
24434750
PMCID:
PMC3894558
DOI:
10.1038/srep03743
[Indexed for MEDLINE]
Free PMC Article
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for Nature Publishing Group Icon for PubMed Central
    Loading ...
    Support Center